Galectin-3 (encoded by the LGALS3 gene) is a member of the galectin family of beta-galactoside-binding lectins that plays a multifaceted role in neurodegenerative disease pathogenesis. Unlike other galectins, Galectin-3 contains a unique N-terminal proline-rich domain that enables its involvement in diverse cellular processes including cell adhesion, apoptosis, immune response, and phagocytosis 1. In the central nervous system, Galectin-3 is primarily expressed in microglia, the resident immune cells of the brain, where it serves as a key marker of disease-associated microglia (DAM) or neurodegenerative microglia (NG2) 2.
The protein has attracted significant attention as both a biomarker of neuroinflammation and a potential therapeutic target. Elevated Galectin-3 levels have been documented in brain tissue and cerebrospinal fluid from patients with Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and multiple sclerosis 3. Its involvement in microglial activation, amyloid-beta clearance, tau pathology, and neuroinflammation makes it a critical molecule in the neurodegenerative process.
¶ Gene and Protein Structure
The LGALS3 gene is located on chromosome 14q22.3 and encodes a 250 amino acid protein. The gene structure includes:
- 6 exons spanning approximately 17 kb
- Multiple transcription start sites
- Conserved promoter elements for immune and tissue-specific regulation
Galectin-3 has a distinctive structure consisting of:
- N-terminal domain (amino acids 1-110): Proline-rich region enabling oligomerization and protein-protein interactions
- Carbohydrate recognition domain (CRD) (amino acids 111-250): Conserved galactose-binding motif enabling carbohydrate recognition
- C-terminal tail: Critical for lectin activity and multimerization
The ability of Galectin-3 to form oligomers enables cross-linking of glycoproteins on cell surfaces and extracellular matrices, facilitating functions in adhesion, signaling, and phagocytosis 4.
In the healthy brain, Galectin-3 expression is limited:
- Microglia: Low baseline expression, dramatically upregulated in disease states
- Astrocytes: Moderate expression in reactive astrocytes
- Neurons: Minimal expression under normal conditions
Galectin-3 has emerged as one of the most robust markers for disease-associated microglia (DAM) or microglia in the neurodegenerative (NG) phenotype 5. The DAM phenotype represents a distinct activation state characterized by:
- Upregulation of lipid metabolism genes
- Enhanced phagocytic activity
- Production of pro-inflammatory cytokines
- Response to neuronal damage signals
Galectin-3 interacts with amyloid-beta (Aβ) plaques in multiple ways:
- Plaque association: Galectin-3 colocalizes with Aβ plaques in AD brain tissue, indicating direct binding to Aβ aggregates
- Modulation of aggregation: Galectin-3 can influence Aβ aggregation kinetics through carbohydrate-binding interactions
- Phagocytosis enhancement: The protein enhances microglial phagocytosis of Aβ through receptor-mediated mechanisms 6
Galectin-3 involvement in tau pathology includes:
- Association with neurofibrillary tangles (NFTs) in AD brain
- Potential role in tau spreading between neurons
- Interaction with tau kinases and phosphatases affecting phosphorylation state
As a key mediator of neuroinflammation, Galectin-3:
- Binds to activated microglia via TLR4 and other pattern recognition receptors
- Triggers production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6
- Amplifies inflammatory cascades in the AD brain
- Promotes chronic neuroinflammation that drives disease progression 7
In PD and related synucleinopathies, Galectin-3 participates in:
- Interaction with Lewy bodies containing aggregated alpha-synuclein
- Modulation of microglial responses to alpha-synuclein
- Potential role in the spread of pathological alpha-synuclein
Galectin-3 contributes to neuroinflammation in PD through:
- Activation of microglia in the substantia nigra
- Promotion of dopaminergic neuron loss
- Enhancement of neurotoxicity through inflammatory mediators 8
¶ Role in ALS and Other Neurodegenerative Diseases
In ALS, Galectin-3 is involved in:
- Microglial activation in motor cortex and spinal cord
- Progression of motor neuron degeneration
- Interaction with aggregates containing TDP-43
Elevated Galectin-3 has been reported in:
- Multiple sclerosis
- Huntington's disease
- Frontotemporal dementia
- Traumatic brain injury
Galectin-3 in CSF represents a promising biomarker:
- Elevated levels in AD, PD, and ALS patients compared to controls
- Correlates with disease severity and progression
- Potential for differential diagnosis 9
Peripheral Galectin-3 measurement shows:
- Increased circulating levels in neurodegenerative disease
- Association with inflammatory markers
- Potential for disease monitoring
Galectin-3 represents a therapeutic target through:
- Inhibition: Small molecule inhibitors and neutralizing antibodies
- Modulation: Strategies to shift microglial phenotype toward anti-inflammatory state
- Downstream signaling: Targeting pathways activated by Galectin-3
Pharmaceutical companies are developing:
- Galectin-3 inhibitors for neuroinflammatory diseases
- Antibody-based therapies
- Modulators of galectin-3 dependent signaling
Key methods for studying Galectin-3:
- Immunohistochemistry: Detection in brain tissue sections
- ELISA: Quantification in CSF and blood
- Western blot: Protein expression analysis
- qPCR: Gene expression studies
Research utilizes:
- Transgenic mouse models of AD and PD
- Primary microglial cultures
- iPSC-derived neurons and microglia
- Galectin-3 knockout mice
Galectin-3 measurement may aid in:
- Early detection of neurodegeneration
- Differential diagnosis between subtypes
- Monitoring disease progression
Elevated Galectin-3 correlates with:
- Faster disease progression
- Greater cognitive decline
- Reduced treatment response
¶ Interactions and Signaling Pathways
Galectin-3 interacts with:
- TLR4: Pattern recognition receptor triggering inflammation
- CD36: Scavenger receptor mediating phagocytosis
- RAGE: Receptor for advanced glycation end products
- Integrins: Cell adhesion molecules
Galectin-3 activates multiple pathways:
- NF-κB: Master regulator of inflammation
- MAPK pathways: Cell stress and inflammatory signaling
- PI3K/Akt: Cell survival and metabolic regulation
Genetic variants in LGALS3 have been associated with:
- Altered disease risk in some populations
- Modification of age of onset
- Response to therapeutic interventions